AstraZeneca’s ZD4054 Phase II Shows 24.5-Month Overall Survival In Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Median survival rates in metastatic hormone-resistant prostate cancer improve on Taxotere by more than five months; Phase III trials of ZD4054 will begin this year.
You may also be interested in...
Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings
Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
Taxotere is the first drug to demonstrate a survival benefit in hormone refractory patients, FDA said. Aventis is investigating docetaxel as first-line therapy.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.